🔗 Visit the ClinicalTrials.gov page for NCT01279694
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Can we change the disease biology of multiple myeloma? | Leuk Res | 2012 | 0.98 |
| 2 | Phase 1/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma. | Blood | 2015 | 0.83 |
| 3 | Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib. | Biologics | 2013 | 0.81 |